About me
Dr. Nadir Mahmood serves as President of Nkarta, where he is responsible for driving the company’s strategic focus, business excellence, and technical success. He previously served as the Chief Executive Officer of Rezo Therapeutics, a private-stage drug discovery company. Prior to joining Rezo Therapeutics, Dr. Mahmood served as Chief Financial and Business Officer at Nkarta, where he played a direct role in corporate strategy, including the company’s private and public financings as well as the formation of its in-house cell manufacturing capabilities. Earlier in his career, Dr. Mahmood led corporate development at Second Genome. Previously, he was a staff scientist at Kythera Biopharmaceuticals, where he oversaw preclinical research for the company’s lead molecule, Kybella®. Dr. Mahmood has also worked in equity research at Goldman Sachs and consulted for early-stage companies in the life sciences and clean energy sectors.
He earned a B.S. in biochemistry from the University of Texas at Austin and a Ph.D. in cell regulation from the University of Texas Southwestern Medical Center, and completed postdoctoral research at the Scripps Research Institute in La Jolla, CA.
